Inclusion Criteria:  Age ≥ 18 Confirmed diagnosis of multiple myeloma Newly-diagnosed multiple myeloma, or relapsed/refractory multiple myeloma with receipt of 1-3 previous lines of therapy and with a 2-week washout from prior therapy Receiving carfilzomib as either standard-of-care therapy or as part of a clinical trial  Exclusion Criteria:  Previous receipt of anthracycline chemotherapy Previous receipt of carfilzomib Four or more previous lines of therapy Active pregnancy at the time of enrollment